24 March 2017

The Cannabist reports

A synthetic THC drug just cleared a federal regulatory hurdle to commercialization.

Insys Therapeutics, a Chandler, Ariz.-based pharmaceutical firm, said Thursday its U.S. Food and Drug Administration-approved liquid dronabinol drug Syndros could launch later this year after the synthetic THC oral solution received an initial go-ahead for Schedule II classification under the Controlled Substances Act, which would allow doctors to prescribe it.

“Insys is looking forward to bringing this new drug product to chemotherapy patients to help alleviate their nausea and vomiting and AIDS patients with anorexia-associated weight loss, respectively,” Insys interim CEO Dr. Santosh Vetticaden said in a statement. “We look forward to interacting with the FDA to finalize the labeling and subsequent launch of Syndros in the second half of 2017.”

Full report at